PF PRISM CV Company Profile

✉ Email this page to a colleague

PF PRISM CV has sixteen approved drugs.

There are twenty-nine US patents protecting PF PRISM CV drugs.

There are six hundred and twelve patent family members on PF PRISM CV drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-003	Feb 23, 2004		DISCN	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-002	Sep 4, 2012		RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012		RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	8,791,140	⤷ Try a Trial		Y		⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-002	Aug 22, 2002	5,212,155*PED	⤷ Try a Trial
Pf Prism Cv	RAPAMUNE	sirolimus	SOLUTION;ORAL	021083-001	Sep 15, 1999	5,100,899*PED	⤷ Try a Trial
Pf Prism Cv	TORISEL	temsirolimus	SOLUTION;INTRAVENOUS	022088-001	May 30, 2007	8,455,539*PED	⤷ Try a Trial
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-003	Oct 27, 2017	6,002,008	⤷ Try a Trial
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	RE40183	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	25 mg	➤ Subscribe	2015-05-08
➤ Subscribe	Tablets	1 mg and 5 mg	➤ Subscribe	2018-02-23
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2018-10-15
➤ Subscribe	Tablets	50 mg and 200 mg	➤ Subscribe	2008-04-14
➤ Subscribe	For Injection	50 mg per vial	➤ Subscribe	2009-06-15
➤ Subscribe	Tablets	1 mg and 2 mg	➤ Subscribe	2009-12-17
➤ Subscribe	Extended-release Tablets	50 mg and 100 mg	➤ Subscribe	2012-02-29
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Tablets	5 mg	➤ Subscribe	2016-11-07
➤ Subscribe	Tablets	100mg and 500mg	➤ Subscribe	2016-09-06
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2008-09-12
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2010-10-08
➤ Subscribe	Injection	25 mg/mL, 1.8 mL vial	➤ Subscribe	2011-05-25
➤ Subscribe	Tablets	0.5 mg	➤ Subscribe	2010-08-25

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1786785	2013/009	Ireland	⤷ Try a Trial	PRODUCT NAME: PRODUCT (I.E. ACTIVE INGREDIENT OR COMBINATION OF ACTIVE INGREDIENTS) FOR WHICH A CERTIFICATE IS REQUESTED: CRIZOTINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/12/793/001 EU/1/12/793/004 20121023
0536515	06C0031	France	⤷ Try a Trial	PRODUCT NAME: TIGECYCLINE; REGISTRATION NO/DATE: EU/01/06/336/001 20060424
1218348	2013/008	Ireland	⤷ Try a Trial	PRODUCT NAME: AXITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/777/001 EU/1/12/777/006 20120903
0648494	C00648494/01	Switzerland	⤷ Try a Trial	PRODUCT NAME: SIROLIMUS; REGISTRATION NO/DATE: IKS 55243 20000926
1218348	C 2013 006	Romania	⤷ Try a Trial	PRODUCT NAME: AXITINIB,OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/12/777/001, RO EU/1/12/777/002, RO EU/1/12/777/003, RO EU/1/12/777/004, RO EU/1/12/777/005, RO EU/1/12/777/006; DATE OF NATIONAL AUTHORISATION: 20120903; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/12/777/001, EMEA EU/1/12/777/002, EMEA EU/1/12/777/003, EMEA EU/1/12/777/004, EMEA EU/1/12/777/005, EMEA EU/1/12/777/006; DATE OF FIRST AUTHORISATION IN EEA: 20120903
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.